Early Alzheimer's Pathology May Trigger Diabetes
Furthermore, inasmuch as the typical age of onset of type 2 diabetes is earlier than that of AD, it may be that the pathologic processes of AD are occurring in the brain much earlier than the symptoms and are leading to some cases of type 2 diabetes ...
Medscape - Thu, 21 Apr 2016 08:56

FDA Approves Cabometyx for Advanced RCC
Compared with everolimus, a standard of care therapy for second-line RCC, cabozantinib was associated with a 42% reduction in the rate of disease progression or death. Median PFS for cabozantinib was 7.4 versus 3.8 months for everolimus (hazard ratio ...
Pharmacy Practice News - Wed, 27 Apr 2016 12:24



4 Stocks To Watch In The Race For New Liver Treatments
The race to bring new liver disease treatments to market has been gathering strong momentum as the potential prize for a multi-billion dollar payoff fuels the competition. According to a recently released report (Liver Diseases Treatments: The Global ...
Seeking Alpha - Wed, 27 Apr 2016 09:18



Cabozantinib (Cabometyx) Wins FDA Nod for Patients With Advanced Renal Cell ...
... receptor (VEGFR)-1, -2 and -3. In preclinical models, the drug inhibited the activity of these receptors, which are involved in both normal cellular function and pathologic processes, such as tumor angiogenesis, invasiveness, metastasis, and drug ...
Managed Care magazine - Tue, 26 Apr 2016 12:52

ADDING MULTIMEDIA Exelixis Announces FDA Approval of CABOMETYX™ (Cabozantinib ...
Yahoo Finance UK - Mon, 25 Apr 2016 10:48

Cabometyx Approved for Advanced Renal Cell Carcinoma
Monthly Prescribing Reference (registration) - Mon, 25 Apr 2016 13:03

US FDA approves Exelixis' Cabometyx tablets to treat advanced RCC who have ...
pharmabiz.com - Wed, 27 Apr 2016 02:45



NC Biotechnology Center awards $2.5M in latest round of grants, loans
A $250,000 Small Business Research Loan to BioMedomics of Research Triangle Park will support the development of a low-cost, point-of-care test for hemoglobin variants in blood, to aid in effective treatment decisions for sickle cell disease. A $250 ...
WRAL Tech Wire - Tue, 26 Apr 2016 09:07



Reproducibility of the NEPTUNE descriptor-based scoring system on whole-slide ...
Ultrastructural podocyte descriptors were scored by five pathologists with 1 to >10 years of experience on 178 cases (minimal change disease/focal segmental glomerulosclerosis) as follows: foot process effacement: 0=1–10%, 1+=11–25%, 2+=26–50%, ...
Nature.com - Fri, 22 Apr 2016 04:37

Angiogenesis factor found to promote three age-related diseases of the eye
"Our finding that shared pathologic mechanisms contribute to these three conditions identifies potential molecular targets for treating or even preventing their development," says Alexander Marneros, MD, PhD, of the MGH Cutaneous Biology Research ...
Science Daily - Tue, 12 Apr 2016 09:30



Preventing and Treating Bone Metastases in mCRPC
Bone metastases in metastatic castration-resistant prostate cancer (mCRPC) can invade a range of sites in the skeleton where they precipitate a spectrum of pathological processes that increase morbidity, negatively affect quality of life, and decrease ...
Targeted Oncology - Mon, 18 Apr 2016 11:45


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.